The Economics Behind U.S. Generic Drug Manufacturing: Part One
In this episode of Off Script, we spoke with John Murphy III, president and CEO of the Association for Accessible Medicines, about the forces shaping the future of U.S. generic and biosimilar manufact...
20 Nov 202516min
CGT Manufacturing Challenges and Opportunities
While the cell and gene therapy space represents one of the most exciting therapeutic frontiers in modern biopharma by offering highly personalized, transformative treatments, the sector still faces s...
11 Nov 202519min
The State of CDMO Funding: 2025 in Review (Part Two)
In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today’s CDMO funding trends are shaping the next phase of growth and speciali...
4 Nov 202517min
The State of CDMO Funding: 2025 in Review (Part One)
As we near the end of 2025, the CDMO industry finds itself at a pivotal financial and strategic juncture — shaped by constrained funding, shifting demand, and renewed investor scrutiny. In this episo...
28 Okt 202522min
Corporate compliance involves more than just cGMP and quality
This episode of Off Script: A Pharma Manufacturing Podcast features a conversation with Jana Falkenberg, senior legal counsel and corporate compliance officer at Vetter Pharma, a global contract devel...
17 Okt 202516min
Charting Pharma Manufacturing Trends: Part Two
Building on insights from CRB’s Horizons: Life Sciences 2025 report, this second installment of our conversation with Peter Walters, Fellow of Advanced Therapies at CRB, explores the modalities drivin...
14 Okt 202516min
Charting Pharma Manufacturing Trends: Part One
Based on insights from CRB’s Horizons: Life Sciences 2025 report, this episode of Off Script: A Pharma Manufacturing Podcast features a conversation with Peter Walters, Fellow of Advanced Therapies at...
7 Okt 202513min
Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers
Large biopharma companies in recent months have pledged billions of dollars in capital expenditures for U.S. manufacturing and R&D facilities. What if it’s not accurate? Greg Slabodkin Read by Br...
16 Sep 20254min
